Single-Tablet Regimen Containing Rilpivirine and Dolutegravir Being Developed for HIV

June 18, 2014

A single-tablet formulation containing two drugs is currently being developed as maintenance therapy for people living with HIV. The new medication, being developed by Janssen R&D Ireland Ltd and ViiV Healthcare, will combine the NNRTI (non-nucleoside reverse transcriptase inhibitor) rilpivirine (Edurant) and the integrase inhibitor dolutegravir (Tivicay, DTG).

If successfully developed and approved, patients who are already virologically suppressed using a standard three-drug regimen could switch to a two-drug, NRTI (nucleoside reverse transcriptase inhibitor)-sparing regimen. The companies will also look into developing the regimen for pediatric use.

"This is an exciting development that builds on the momentum of the dolutegravir program and early success of the nuke-sparing, two-drug maintenance strategy investigated in the LATTE clinical trial," Benjamin Young, M.D., Vice President of IAPAC, told

"This may be the first place that nuke-sparing actually gets a toe hold into the panoply of HIV treatments. How Janssen and ViiV commercialize the product will be critical, as the combo pill will no doubt be launched into a U.S. market with fully generic alternatives. It will be very interesting to watch its future development," Young further added.

Read the full press release.

Warren Tong is the research editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2014 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.